Identification of Small Molecule Activators of BMP Signaling

Karen Vrijens¹, Wenwei Lin², Jimmy Cui², Dana Farmer¹, Jonathan Low², Elodie Pronier¹,³, Fu-Yue Zeng², Anang A. Shelat², Kiplin Guy², Michael R. Taylor², Taosheng Chen², Martine F. Roussel¹*

¹Departments of Tumor Cell Biology, Memphis, Tennessee, United States of America, ²Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America, ³Institut National de la Sante´ et de la Recherche Medicale, U1009, Institut Gustave Roussy, Villejuif, France

Abstract

Bone Morphogenetic Proteins (BMPs) are morphogens that play a major role in regulating development and homeostasis. Although BMPs are used for the treatment of bone and kidney disorders, their clinical use is limited due to the supra-physiological doses required for therapeutic efficacy causing severe side effects. Because recombinant BMPs are expensive to produce, small molecule activators of BMP signaling would be a cost-effective alternative with the added benefit of being potentially more easily deliverable. Here, we report our efforts to identify small molecule activators of BMP signaling. We have developed a cell-based assay to monitor BMP signaling by stably transfecting a BMP-responsive human cervical carcinoma cell line (C33A) with a reporter construct in which the expression of luciferase is driven by a multimerized BMP-responsive element from the Id1 promoter. A BMP-responsive clone C33A-2D2 was used to screen a bioactive library containing ~5,600 small molecules. We identified four small molecules of the family of flavonoids all of which induced luciferase activity in a dose-dependent manner and ventralized zebrafish embryos. Two of the identified compounds induced Smad1, 5 phosphorylation (P-Smad) Id1 and Id2 expression in a dose-dependent manner demonstrating that our assays identified small molecule activators of BMP signaling.

Citation: Vrijens K, Lin W, Cui J, Farmer D, Low J, et al. (2013) Identification of Small Molecule Activators of BMP Signaling. PLoS ONE 8(3): e59045. doi:10.1371/journal.pone.0059045

Editor: Qiming Jane Wang, University of Pittsburgh School of Medicine, United States of America

Received August 17, 2012; Accepted February 11, 2013; Published March 19, 2013

Copyright: © 2013 Vrijens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded in part by grants from the National Institutes of Health CA-096832 (MFR) and Core Grant CA-21765 (MFR, TC, KG), the James McDonnell Foundation www.jmfn.org (MFR), the Jennifer Lynn Keith American Brain Tumor Association Basic Research Fellowship www.abta.org (K), the American Association for Cancer Research-Astellas United States of America Foundation Fellowship in Basic Cancer Research www.aacr.org (KV), and the American Lebanese-Syrian Associated Charities of St. Jude Children's Research Hospital www.stjude.org. No individuals from the funders contributed to this work. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: martine.roussel@stjude.org

Introduction

Bone Morphogenetic Proteins (BMPs) are a class of morphogens belonging to the transforming growth factor β (TGF-β) superfamily, that were originally discovered because of their bone inducing capabilities [1,2,3]. The BMP family contains over 20 members with a wide array of functions, including embryonic patterning and development [4], stem cell renewal and differentiation [5], and tissue homeostasis [6]. BMPs signal through type I and type II serine/threonine kinase BMP receptors (BMPRs) (Figure 1). Humans have three type I BMP receptors, BMPR-IA (Alk3), BMPR-IB (Alk6) and the type IA Activin (Alk2) receptor that binds activins and TGFβ as well as BMPs [7,8]. BMPR-II is the only type II receptor [9]. Ligand binding induces the formation of a hetero-tetrameric receptor complex composed of two BMPR-IA and/or BMPR-IB receptors and two BMPR-II receptors and activates their kinase activity [10]. In turn, the activated complex recruits Smad1, 5, or 8 from the repressor Smad6 and phosphorylates (P) them at the C-terminus, an obligatory step in the canonical BMP signaling pathway [11,12]. P-Smad1, 5, or 8 forms a complex with Smad4 that is translocated to the nucleus and binds to BMP responsive elements (BRE) on the promoters of specific target genes, including the inhibitors of differentiation/DNA-binding 1–4, (Id1–4) [13].

Several endogenous antagonists of the pathway have been identified, including Noggin, which prevents BMPs from binding to the trans-membrane receptors (Figure 1) [14]. BMP signaling can also be mediated by Smad-independent pathways that are dependent on MAPK, and can lead to apoptosis or activation of downstream target genes through p38, JNK or Erk [15].

Medulloblastoma, a tumor of the cerebellum, is the most common malignant pediatric brain cancer [16,17]. It is molecularly characterized into four groups; one of which sustains mutations that constitutively activate the Sonic Hedgehog (SHH) signaling pathway [18,19]. BMP-2 and -4 signaling antagonizes SHH-dependent proliferation by inducing the irreversible differentiation of cerebellar granule neuron progenitors (GNPs) [20] and of medulloblastoma cells [21]. BMPs cause rapid turnover of the basic-helix-loop-helix transcription factor Atonal (Atoh1, Math1 in mice) [21] which is required for cerebellum development [14] and tumor formation [22]. GNPs from mice lacking Math1 fail to proliferate and animals are born with a cerebellum lacking the external germinal layer [14]. Deletion of Math1 in a mouse model of SHH-group medulloblastoma in which the SHH receptor Patched (Pch) is mutated completely inhibits tumor development [22]. In mouse and human SHH-group medulloblastoma, genes in the BMP signaling pathway are down-regulated [21]. The SHH antagonist cyclopamine acts additively with BMP-
2, and -4 to suppress GNPs and SHH-group medulloblastoma suggesting that BMP agonists could be used in combination with SHH-antagonists, both potentially at lower levels than alone, to reduce the potential side effects of the individual targeted therapies. The SHH-antagonist HH-Antag induces bone defects when administered to young tumor prone mice [23] and a patient treated with the SHH-antagonist GDC-0449 became resistant to the drug due to mutations in the targeted receptor Smoothened (SMO) [24]. Because recombinant BMPs are expensive to produce and are unlikely to cross the blood-brain barrier, small molecule activators of BMP signaling could provide a cost-effective alternative that are therapeutically available. In addition, the systemic administration of supra-physiological levels of BMPs as therapeutic agents induces severe side effects including inflammation, edemas and heterotopic bone formation [25]. Thus, small molecule activators of BMP signaling may be more efficacious when used at lower levels mitigating the possible undesirable side effects. Although several inhibitors of the BMP signaling pathway have been identified, including the synthetic antagonist dorsomorphin [26], to date, no small molecules have been shown to activate canonical BMP signaling. We here report our efforts to identify small molecule activators of the BMP signaling pathway.

Methods

Ethics Statement

Zebrafish were housed in an accredited facility of the Association for Assessment of Laboratory Animal Care (AALAC) in accordance with the National Institutes of Health guidelines. The Institutional Animal Care and Use Committee (IACUC) permit number A3077-01 of SJCRH approved all procedures in this study.

All animal work conducted to obtain primary medulloblastoma cells was performed under established guidelines and supervision by the St. Jude Children’s Research Hospital’s Institutional Animal Care and Use Committee (IACUC), as required by the United States Animal Welfare Act and the National Institutes of Health’s policy, to ensure proper care and use of laboratory animals for research under the protocol # 378.

Cell Lines and Tissue Culture

The human cervical carcinoma cell line C33A (ATCC, Manassas, VA) was maintained in Eagle’s minimum essential medium (EMEM) supplemented with 10% FBS, 2 mM glutamine, 500 units/ml penicillin and 500 μg/ml streptomycin and grown at 37°C and 8% CO₂. The C33A-2D2 subclone and C33A-C control cells we generated were grown in the same medium in the presence of 200 μg/ml Hygromycin B (Invitrogen, Carlsbad, CA). For the cell-based assay, C33A-2D2 and C33A-C control cells were re-suspended in EMEM without phenol red, supplemented with 0.25% FBS, 500 units/ml penicillin and 500 μg/ml streptomycin, and 2 mM glutamine. C2C12 (ATCC, Manassas, VA) cells were grown in DMEM supplemented with 10% FBS, 500 units/ml penicillin and 500 μg/ml streptomycin and 2 mM glutamine, at 37°C and 8% CO₂. To avoid depletion of the myoblastic...
population, cells were not allowed to grow to confluence but were passaged at a density less than 70%. NIH3T3 (ATCC, Manassas, VA) and HeLa (ATCC, Manassas, VA) cells were maintained in DMEM supplemented with 10% FBS and cultured at 37°C and 8% CO₂. DAOY cells (ATCC, Manassas, VA) were maintained in EMEM supplemented with 10% FBS and cultured at 37°C and 8% CO₂. Primary medulloblastoma cells were purified by Percoll density gradient from spontaneous tumors arising in Pchh+/-, Cdkn2c-/- mice, as described previously [27]. For use in the assays, 2×10⁶ tumor cells were plated in 6-well dishes, allowed to attach overnight, and treated with BMP-4 or DMSO added to the culture medium. After 24 hrs, cells were trypsinized for 5 minutes at 37°C and harvested using an equal amount of ovoevent solution. Samples were centrifuged, cell pellets frozen in dry ice and processed for western blotting as described below.

**Compound libraries selection**

The screening library consisted of 5,600 (approximately 3,200 unique) approved drugs and chemicals with known biological activity (“St. Jude bioactives”). The library was assembled from 3 commercial suppliers: Microsource, Prestwick, and Sigma. The Microsource compounds included (a) the Spectrum collection, which contains 2,000 biologically active and structurally diverse compounds, including known drugs, experimental bioactives, and pure natural products, (b) the US Drug Collection, which contains 1,040 drugs that have reached clinical trials in the US and have been assigned USAN or US Pharmacopoeia status; and (c) the Killer collection, which contains a reference set of 160 synthetic and natural toxic substances (http://www.msdiscovery.com/index.html). The Prestwick compounds include 1,120 small molecules selected for high chemical and pharmacologic diversity. Ninety percent of the collection is composed of known marketed drugs, and the remainder includes bioactive alkaloids or related substances. Human bioavailability and human toxicity data are available for most compounds (http://www.prestwickchemical.fr/index.php?pa = 26. Accessed 2013 February 13). The Sigma LOPAC® (Library of Pharmacologically Active Compounds) collection reflects the most commonly screened targets in the drug discovery community, including marketed drugs, failed development candidates, and “gold standards” that have well-characterized activities (http://www.sigmaaldrich.com/catalog/product/sigma/lo1280?lang = en&region = US. Accessed 2013 February 15) [28].

**High Throughput Screening (HTS)**

C33A-2D2 cells were seeded into white, solid-bottom, tissue culture-treated, 384-well polystyrene plates at a density of 5×10⁴ cells per well in 25 μl media. Compounds, BMP-4 (positive control), or DMSO (negative control) were transferred with a V&P 384-well pintool at 30 nl/well to give a final compound concentration of 12 μM into individual wells. The final positive BMP-4 control concentration was 100 ng/ml and the final DMSO concentration was 0.12%. The assay plates were then incubated overnight at 37°C, 5% CO₂, 95% relative humidity followed by luminescence assay for luciferase reporter activity with SteadyLite HTS reagent. Activity data were normalized to 100 ng/ml of BMP-4 as 100% activation and 0.12% DMSO as 0% activation. For unique hits identified in the primary screening, dose response (DR) assays were implemented in triplicate against the C33A-2D2 cells in the same HTS setting at ten different concentrations, following a 3 fold dilution scheme from 36 μM down to 2.8 nM. Similarly, a BMP-4 dilution series from 100 ng/ml to 0.2323 fg/ml was used as control. To measure luciferase activity, we used a luminescent SteadyLite assay, as per manufacturer’s instructions (PerkinElmer, manual 44-73605, Waltham, MA). Cells were lysed after a 24 hr treatment period by addition of SteadyLite reagent and luminescence was measured using a 2102 EvaView plate reader (PerkinElmer, Waltham, MA).

**Immunoblotting**

C33A-2D2 cells were seeded into clear 6-well plates at a density of 4×10⁴ cells per well in 2 ml of medium. Cells were serum-starved for 6 hours and treated or not with each of the four compounds at concentrations of 5, 10, 18 and 24 μM for 24 hours. 10 ng/ml human recombinant BMP-4 (R&D systems, Minneapolis, MN) and 0.1% DMSO were included as positive and negative control, respectively. After collection, cells were homogenized in RIPA lysis buffer (50 mM Tris, pH 7.4; 150 mM NaCl; 0.1% SDS; 0.5% Sodium deoxycholate and 1% Triton X100), to which a cocktail of protease inhibitors (1 mM PMSF; 38 μg/ml aprotinin, 10 mM β-glycerophosphate; 1 mM NaF and 100 μM NaVO₄) was added immediately before use. Proteins were quantified using a bicinechonic acid (BCA) protein assay reagent (Pierce, Rockford, IL) according to the manufacturer’s instructions. 20 μg of protein per sample were analyzed using a 10% SDS-PAGE gel for the detection of P-Smad1, 5 and Smad1,5 (PerkinElmer, manual 44-73605, Waltham, MA). Cells were lysed after a 24 hr treatment period by addition of SteadyLite reagent and luminescence was measured using a 2102 EvaView plate reader (PerkinElmer, Waltham, MA).

**Figure 2. Development and validation of a cell-based assay.**

(A.) Response of different established cell lines NIH3T3, HeLa and DAOY to stimulation for 24 hrs with (+) or without (−) 20 ng/ml BMP-4. The clonal cell line C33A-2D2, showed induction of phosphorylation of Smad1, 5 and of Inhibitor of DNA binding 1 (Id1)1 expression in response to BMP-4 treatment. Primary medulloblastoma cells (MB) from Pchh+/-/Cdkn2c-/- mice are shown as a positive control. (B.) Response of C33A-2D2 and C33A-C control cells to BMP-4 measured as raw luminescent activity (RLU). C33A-2D2 displays a saturated sigmoidal dose-response curve in response to BMP-4 stimulation with an EC₅₀ value of 0.3 ng/ml BMP-4 (green curve). C33A-C (empty vector) is completely unresponsive to BMP-4 treatment (red curve). Both cell lines were treated with a dilution series (1/3) of BMP-4 from 100 ng/ml as top concentration. 24 hrs later, luciferase activity was assayed using SteadyLite reagent. (C.) Antagonistic properties of the endogenous protein Noggin (red line) and the small molecule dorsomorphin (blue line) on BMP-4 (green line) in C33A-2D2 cells. Both molecules completely inhibited Id1 promoter activity at lower concentrations of BMP-4. At higher concentrations of BMP-4 (>10 ng/ml Noggin) could no longer compete with BMP-4 to prevent it from binding to the BMP receptors. The green line represents 1 to 3 dilution series of BMP-4 with the top concentration of 100 ng/ml. The red line represents BMP-4 dilution series containing a fixed concentration of Noggin at 250 ng/ml. The blue line represents a BMP-4 dilution series containing a fixed concentration of 10 μM dorsomorphin.

doi:10.1371/journal.pone.0059045.g002
and a 12% SDS-PAGE gel for Id1 and Id2 detection. After electrophoresis, proteins were transferred to PVDF membranes. Membranes from the 10% gels were blocked in 5% milk/TBS-Tween 2 hours at room temperature (RT), incubated with a rabbit monoclonal antibody anti-P-Smad1, 5 (Cell Signaling # 9516S, Danvers, MA) at 1/500 dilution in 5% BSA TBS/Tween overnight (O/N) at 4 °C or a rabbit polyclonal antibody to Smad1, 5 (SC#6301-R) or to Actin (SC#1615) (all from Santa Cruz Biotechnology, Santa Cruz, CA). We generated a rabbit polyclonal antibody raised against P-Smad1, 5 by immunization of a C-terminal phospho-peptide linked to KLH [VLTQMGSPLNPISS(P)VS(P)], in which the two serines at positions 463 and 465 were phosphorylated. This antibody was used at 1/3000 dilution. For the detection of Id1 and Id2, membranes from the 12% gels were blocked in 5% BSA in TBS/Tween 20 for 2 hours at RT, and incubated O/N in 5% milk/TBS/Tween 20 containing rabbit polyclonal antibodies to Id1 (SC#480), Id2 (SC#489) or Actin (C-11) at 1:500 dilution (all from Santa Cruz Biotechnology, Santa Cruz, CA). Smad-independent BMP signaling was analyzed by (P)-Erk1/2 activation, with primary antibodies against Erk1/2 (MK1, Santa Cruz Biotechnology, Santa Cruz, CA) and P-Erk1/2 (Thr202/Tyr204) (#9101, Cell Signaling, Danvers, MA) at 1:1,000 dilution. Incubation with primary antibodies was followed by incubation with species-specific secondary antibodies for 2 hours (anti-rabbit IgG horseradish peroxidase-linked whole antibody dilution 1:2500 (GE Healthcare, Waukesha, WI) or anti-goat IgG HRP antibody dilution 1:2500 (Invitrogen/Life Technologies, Grand Island, NY) coupled with horseradish peroxidase and proteins were detected by enhanced chemiluminescence (Perkin-Elmer, Waltham, MA). P-Erk levels were quantified by scanning the films from three independent experiments, each normalized to Erk levels as control using Image J software.

Alkaline phosphatase (ALP) assays

C2C12 cells were seeded into 24-well polystyrene plates at a density of 2 x 10^3 cells per well in 500 µl of medium. Cells were allowed to adhere overnight, and were stimulated with increasing concentrations of compounds (1 µM to 10 µM). As positive control we used a dilution series of human recombinant BMP-4 (R&D Systems) with concentrations ranging from 50 ng/ml to 5 ng/ml. Cells were incubated for 6 days, after which we measured levels of ALP. Cells were washed twice with PBS, and 250 µl lysis buffer was added to each well. Plates were incubated for 10 minutes at 4°C under shaking conditions, 250 µl of luminescent substrate (Sensolyte, Anaspec, Fremont, California) was added, and plates were incubated an additional 30 minutes at

![Figure 3. Cell-based assay quality control metrics. (A.) Percent activity scatterplot for all bioactive compounds screened at single point (12 µM) concentration in C33A-2D2 cells. green: positive controls (100 ng/ml of BMP-4); red: negative controls (DMSO); black: screening compounds. Orange line and purple lines represent the 95th and 99th activity percentiles, respectively, of the screening compound population. (B.) Boxplot of the positive control (green), negative control (red), and screening compound populations (black with gray outline). (C.) z-prime in the order of plates screened. (D.) Heatmap of well activity z-scores averaged over all plates in this screen. Columns 1 and 2 were reference dose-response curves for BMP-4 (100 ng/ml top concentration, followed by 1 to 3 dilutions down the column). Column 13 and 14 were the negative and positive controls, respectively. There were no significant plate artifacts in this assay. doi:10.1371/journal.pone.0059045.g003]
Luminescence was measured using a Synergy 2 plate reader (Biotek, Winooski, VT).

Immunohistochemical assays

To examine ALP activity histochemically, $2 	imes 10^4$ C2C12 cells were plated in 6-well plates and allowed to grow overnight in medium with 10% FBS. The next morning, medium was replaced with fresh medium containing 5% FBS. After 3 hours, BMP-4 or compounds were added, and cells were cultured for 6 days. Cells were fixed for 10 minutes with 3.7% formaldehyde at room temperature, washed with PBS and incubated for 20 minutes with 0.1 mg/ml naphtol AS-BI alkaline solution, 0.1 mg/ml Fast Blue benzamidine (FBB)-alkaline solution and 2 µM sodium nitrite solution (all reagents from Sigma-Aldrich, St. Louis, MO). After 20 minutes, cells were washed with PBS and images taken using a Canon Powershot A650 AS.

Zebrafish ventralization assay and morpholino injections

Wild-type zebrafish (Danio rerio) embryos of the TL strain were produced by natural spawning and maintained in egg water (0.03% Instant Ocean) at 28.5 °C. Embryos at 2 hpf were placed in 24-well plates (n = 15 per treatment) and treated with...
Compounds at a concentration range of 1 μM to 80 μM. At 24 and 50 hpf, embryos were manually dechorionated and imaged. Morpholino knockdown of chordin was performed as previously described [29]. Briefly, embryos at the 1 to 2-cell stage were microinjected with approximately 8 ng of chordin morpholino, manually dechorionated, and imaged at 24 hpf.

Results and Discussion

Current treatment strategies for patients with medulloblastoma are often insufficient, since 30% of patients succumb to their disease and survivors suffer from severe neurocognitive side effects. BMP-2 and BMP-4 irreversibly induce the differentiation of SHH-subgroup medulloblastoma in mouse models [21]. However, they cannot be used in a clinical setting to treat pediatric brain tumors because in addition to their cost, the size of recombinant BMP proteins prevent their penetration across the blood brain barrier [30]. Dura fibrosis was observed in pediatric patients treated with BMP-2 [31]. This has prompted us to identify small molecule agonists/activators of the BMP signaling pathway that could be used to treat medulloblastomas of the SHH-subgroup ideally in combination with SHH antagonists. We developed a cell-based high throughput screening (HTS) assay and several secondary assays to identify compounds that activate BMP signaling. We here report a screen of a bioactive library of approximately 5,600 individual compounds. We identified four small molecules of the family of flavonoids including two flavones and two chalcones that induced luciferase activity in a dose-dependent manner and ventralized zebrafish embryos, although only the two flavones activated BMP signaling by inducing Smad1, 5 phosphorylation, as well as Id1 and Id2 protein expression in a dose-dependent manner.

High Throughput Screen cell-based assay

We developed a clonal reporter cell line in which luciferase activity was robustly induced by BMP-4 in a dose-dependent manner. The human cervical carcinoma clonal line, C33A-2D2 gave a robust BMP-4 response and low background compared to other cell lines including NIH3T3, HeLa, DAOY and primary SHH- medulloblastoma cells (Figure 2A). C33A cells were transfected with plasmids modified from a previously described reporter [32] that contained either a multimerized BMP-responsive element (BRE) linked to luciferase (pGL3-BRE-Luc) or an empty vector control (pGL3-Luc) [33]. After selection, hygromycin-resistant cells were subcloned by limiting dilution. The C33A-2D2 subclone induced luciferase levels in a BMP-4 dose-dependent manner (Figure 2B) with an EC50 value of 0.3 ng/ml. Although initially we evaluated the previously published C33H10T1/2 cell line [32], the EC50 for BMP-4 was higher than

### Table 1. Effects of chalcones and flavones on BMP signaling.

| compound class | compound name          | SJ number       | EC50 (μM) | DR primary assay | WB C33A-2D2 | zebrafish |
|----------------|------------------------|-----------------|-----------|------------------|-------------|-----------|
| flavone        | diosmetin              | SJ000286673     | 2.031     | --               | --          | ventralized |
| flavone        | apigenin               | SJ000287098     | 0.952     | --               | --          | ventralized |
| flavone        | biochaninA             | SJ000286709     | 1.485     | --               | --          | normal    |
| flavone        | luteolin               | SJ000287414     | 3.240     | --               | --          | normal    |
| flavone        | biochaninA diacetate   | SJ000287097     | 5.286     | --               | --          | normal    |
| flavone        | isoliquiritigenin      | SJ0002826237    | 8.647     | +                | ventralized |
| flavone        | 4’-hydroxychalcone     | SJ000286396     | 5.197     | +                | ventralized |

(SJ) St Jude Children’s Research Hospital; (DR) dose response; WB: Immunoblotting detecting activation of BMP signaling, phosphorylation of Smad1, 5, and expression of Id1 and Id2 in a dose-dependent manner; (+): significantly different from DMSO; (−): no significant difference from DMSO control (as calculated with student’s t-test). Fold induction was calculated using Image J software. Phenotype of wild type zebrafish embryos was analyzed after treatment with compounds from 2 hpfuntil 30 hpf.

doi:10.1371/journal.pone.0059045.t001

Figure 5. Activation of BMP signaling by the two chalcones isoliquiritigenin and 4’-hydroxychalcone. C33A-2D2 cells were treated either with BMP-4 (+, 10 ng/ml) or increasing concentrations of either isoliquiritigenin (A) or 4’-hydroxychalcone (B). Proteins were separated on either 10% or 12% PAGE gels and immunoblotted with antibodies to phosphorylated Smad-1, 5, total Smad1, 5, 8, Id1 and Id2. Actin was used as loading control.

doi:10.1371/journal.pone.0059045.g005
the current line at 8 ng/ml (Figure S1). In contrast, the control line C33A-C, stably expressing the control reporter construct, did not show induction of luciferase, as expected (Figure 2B). Addition of Noggin or dorsomorphin inhibited the luciferase activity induced by BMP-4, indicating that the assay specifically measured the activation of BMP signaling (Figure 2C).

We adapted the cell-based assay for HTS in 384-well plate format. The assay performed well over a 3-day validation period involving three independent triplicate experiments: average signal to noise was 10, average z-prime was 0.66 [34], and the maximum fold deviation from median EC50 for the positive control, BMP-4, was 1.18. The activity of compounds was calculated as a percent of activation using the following formula: 100* (compound–DMSO)/(BMP-4–DMSO) in which measured values were log10-transformed luciferase Relative Luminescence Units (RLU).

High Throughput Screen of a library of bioactive compounds

We used the optimized assay to screen the ‘bioactives’ compound collection using a fixed concentration of 12 μM BMP-4 (100 ng/mL) and DMSO (0.12%) on each plate as positive and negative controls, respectively. Data was analyzed using a custom informatics application (RISE). The assay demonstrated good discrimination between positive and negative controls, maintained stable signal, and lacked any significant plate artifacts (Figure 3A–D).

Four compounds had activity greater than 50%. One of these, the potent CDK inhibitor kenpaullone (SJ000287948), was excluded from further study. Thirty-two compounds (1% of the unique molecules screened), with activation of BMP signaling between 40–60% relative to BMP-4 (set at 100%), were selected for further study. These compounds were subjected to dose-response studies to determine their potency using the same assay as the primary screen and a top concentration of 56 μM. Selectivity was measured by counter-screening the same dilution plates against the C33A-C line, which measures non-specific luciferase activity. Of these 32 compounds, 19 had potencies below 10 μM with EC50 values ranging from 0.7 to 9 μM, whereas 7 compounds had EC50 values ranging from 12 to 56 μM and 6 compounds did not induce luciferase in a dose-dependent manner. Thus 60% of the initial active compounds were considered validated hits.

Among the 19 validated hits, 4 showed specific activation of BMP signaling; with a good differential in RLU between C33A-2D2 and C33A-C cells. All 4 validated hits were flavonoids, two were chalcones and two were flavones. Chalcones included SJ000286237, called isoliquiritigenin, that had a potency of 10 μM with 80% efficacy and SJ000286396 called 4′-hydroxychalcone with a potency of 10 μM with 90% efficacy (Figure 4, Table 1). The other two small molecules were flavones: SJ000287098, called apigenin, had a potency of 3 μM with 75% efficacy, whereas SJ000286673, called diosmetin, had a potency of 1.5 μM with 80% efficacy (Table 1). Chalcones are a group of aromatic enones that are natural dietary agents. Both chalcones and flavones were shown to have anti-tumor activity [35,36]. However, these effects could possibly be attributed to the interaction with Cytochrome P450 (CYP) genes that metabolize the compounds into other products [37], or to inhibition of specific CYP genes [38]. Therefore, these compounds are not suitable for the further development of small molecules as potential therapeutic drugs.
The two chalcone compounds but not the two flavones activate BMP signaling

Following 24 hrs treatment, the two chalcones, isoliquiritigenin and 4′-hydroxychalcone activated Smad1, 5 phosphorylation, as well as Id1 and Id2 protein expression in a dose-dependent manner (Figure 5). The two other flavonoids, apigenin and diosmetin that induced luciferase failed to activate the pathway (negative data not shown). The difference in the BMP response seen between panels A and B in Figure 5 is a reflection of the size of the wells used in each experiment. We noticed that at 14 μM concentration, 4′-hydroxychalcone reduced the overall level of Smad protein which may be due to toxicity. Although the mechanism by which the two chalcones activate BMP signaling remains unclear, the observed high levels of P-Smad1, 5, Id1 and Id2 protein expression most likely results from inhibition of degradation rather than activation of receptor activity and might be explained by the modulation of their ubiquitination and turnover.

BMPs can also signal through Smad-independent mechanisms, including the MAPK pathway [39]. We assessed the activation of BMP signaling independently of P-Smad1, 5 by analyzing Extracellular Signal-Regulated protein Kinase (Erk) phosphorylation in C33A-2D2 cells treated or not with compounds at 5 and 10 μM. We detected an induction of phosphorylated Erk1/2 (P-Erk1/2) for isoliquiritigenin, 4′-hydroxychalcone and apigenin by immunoblotting (Figure S2A) that was quantified by Image J analysis (Figure S2B). The identification of apigenin as an activator of the MAPK pathway is in agreement with previously published results, since apigenin induces apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes (RA-FLSs) [40], the main constituent of the aggressive front that can invade and destroy local articular structure in rheumatoid arthritis patients [41]. The effect of apigenin on RA-FLSs is mediated by a large increase of intracellular reactive oxygen species; which in turn causes activation of Erk1/2. Moreover, in RA-FLSs, apigenin induced phosphorylation of Erk1/2, without affecting p38 MAPK and JNK phosphorylation [40]. Apigenin and diosmetin that did not induce P-Smad1, 5 could act in a P-Smad-independent fashion. For example, prostacyclin analogs can induce Id1 without affecting Smad1, 5, 8 phosphorylation in a cAMP-dependent manner [42]. It is possible that a similar mechanism of action is responsible for the effects we observe with the two flavones identified in the screen.

Osteoblastic differentiation of mouse myoblasts

C2C12 is a mouse myoblast cell line [43,44] that rapidly differentiates into osteoblasts in response to BMP-4 [45]. One of the hallmarks of osteoblast induction is the expression of alkaline phosphatase (ALP) [46]. ALP is induced in primary osteoblasts by BMP-4 [47]. Although it is widely accepted that BMPs induce ALP in osteoblasts, both canonical (Smad-dependent) and non-canonical (Smad-independent) signaling have been shown to induce ALP in C2C12 cells [39,48]. Isoliquiritigenin was the only
flavonoid that partially differentiated C2C12 cells into osteoblasts compared to BMP-4 treated cells (Figure 6A) although it failed to activate Smad1, 3 phosphorylation or Id1 and Id2 expression in this cell line. Isoquercitrinogen induced an intermediate phenotype between those observed with DMSO and BMP-4 treatment, suggesting that it is less potent than BMP. This result was confirmed by increasing expression levels of ALP in a dose-dependent manner, above DMSO control, providing further functional evidence that this compound is a BMP signaling activator (Figure 6B). Quantification of ALP was performed by measuring luminescence from cleavage of a chemiluminescent substrate (Sensolyte ALP kit, Anaspec). The other chalcone, 4'-hydroxychalcone and the two flavonoid analogs luteolin and biochanin A diacetate did not induce ALP, as expected (negative data not shown).

Activators of BMP signaling ventralize zebrafish embryos

Zebrafish provide an ideal tool to functionally analyze BMP signaling. Small molecule inhibitors of BMP signaling dorsalize embryos [26,49], whereas mutants and morphants for bmp2b, bmp7, and smad5 dorsalize embryos [50], mutants and morphants for chordin ventralize embryos instead [29]. A ventralized phenotype is recognized by decreased to absent dorsal tissues (i.e. brain and eyes), and an abnormal accumulation of cells caudal to the urogenital pore visible at the 26-somite stage [22 hours post fertilization, (hpf)] [51]. In some cases, including the chordin-null mutant, multiple ventral fin folds are observed [52]. We tested whether the four small molecule flavonoids ventralized zebrafish embryos as would be predicted for BMP pathway agonists by treating wild-type embryos from 2 to 50 hpf. All four compounds induced ventralization defects (Figure 7, Table 1). They all induced a decrease in brain size, and treatment with 10 μM 4'-hydroxychalcone, 20 μM apigenin, 10 or 20 μM diosmetin (Figure 7, panel C1, D2 and E1 and E2) resulted in loss of eyes. Treatment with isoliquiritigenin resulted in an abnormal accumulation of cells caudal to the anus (Figure 7B2), and apigenin induced loss of the ventral tail fin (Figure 7D2). Increasing concentrations of compounds in each case caused a more severe phenotype (Figure 7B-E, 1 versus 2). Treatment with DMSO alone failed to affect embryonic development (Figure 7A1) whereas addition of dorsomorphin dorsalized the embryos (Figure 7A2), as previously reported [26]. Injection of chordin morpholino ventralized the embryos (Figure 7A3), as shown previously [29]. To determine if these effects were specific to all flavonoids, we tested compounds from the same chemical class and with similar structures that failed to induce luciferase in the primary assay, biochanin A, luteolin and biochanin A diacetate. They all failed to ventralize zebrafish embryos (Table 1, negative data not shown).

These data suggest that ventralization of zebrafish embryos was induced by the two chalcones that induced BMP signaling but not by all chemicals from the class of the flavonoids [53,54].

In summary, we have established a cell-based reporter assay that identified small molecules activators of BMP signaling. Our results suggest that high throughput screening of a large library of small molecules may identify novel activators of BMP signaling that could be useful in the treatment of medulloblastoma and also for other tumor types, including pediatric germ cell tumors. Because the currently available SHH antagonists lead to bone defects in young mice and to resistance in patients treated with GDC-0449 due to mutations in SMO [24], a combinatorial approach of SHH-antagonists with BMP agonists, possibly at lower doses to minimize side effects, might have therapeutic potential.

Supporting Information

Figure S1 Luciferase activity in response to BMP-4 in C3H10T1/2 cells. C3H10T1/2 mouse embryonic mesenchymal cells were treated for 24 hours with a dilution series (1/3) of BMP-4. 24 hrs later, luciferase was measured as raw luminescent activity (RLU) using Steady-Lite Glo. The calculated EC50 was 8 ng/ml (95% confidence interval was 6–14 ng/ml). The dose-response curve for BMP-4 was not completely saturated at the highest concentration of 300 ng/ml BMP-4. (DOC)

Figure S2 Activation of MAPK signaling. C33A-2D2 cells were treated with 5 μM of compound for 30 minutes, 4, 8 and 24 hours, and with 10 μM of compound for 24 hrs or for 8 hours with 10 ng/ml BMP-4 as positive control, or DMSO as negative control. Protein lysates were immunoblotted with antibodies to P-Erk1/2 and Erk1/2. Representative images are shown for each compound, quantification was performed using Image J analysis software, relative expression levels of P-Erk from 3 independent experiments are shown. (DOC)

We thank Peter Ten Dijke for the gift of the BRE-luciferase plasmid and Herve Peitte for the C3H10T1/2 cell line. We thank Jose Grenet for performing the immunoblots, Dr. Charles J. Sherr and all members of the laboratory for helpful discussions during the course of these studies.

Author Contributions

Conceived and designed the experiments: KV KG MRT TC MFR. Performed the experiments: KV WL JC DF JL EP F-YZ AAS. Analyzed the data: KV MRT TC JL AAS MFR. Contributed reagents/materials/analysis tools: MRT AAS WL. Wrote the paper: KV MFR.

References

1. Canalis E, Economides AN, Gazzarro E (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24: 218–235.
2. Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22: 233–241.
3. Reddi AH, Reddi A (2009) Bone morphogenetic proteins (BMPs): from morphogens to metabologens. Cytokine Growth Factor Rev 20: 341–342.
4. Dale L, Jones CM (1999) BMP signalling in early Xenopus development. Bioessays 21: 731–760.
5. Watabe T, Miyazono K (2009) Roles of TGF-beta family signaling in stem cell renewal and differentiation. Cell Res 19: 103–115.
6. Anderson GJ, Frazer DM, McLaren GD (2009) Iron absorption and metabolism. Curr Opin Gastroenterol 25: 129–135.
7. ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevaz M, et al. (1994) Identification of type I receptors for osteogenic protein-1 and bone morphogenic protein-4. J Biol Chem 269: 16985–16998.
8. Koenig BB, Cook JS, Wolsing DH, Ting J, Tiesman JP, et al. (1994) Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol Cell Biol 14: 3961–3974.
9. Rosenberg BL, Isamara T, Okadome T, Cox GN, Yamashita H, et al. (1995) Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci U S A 92: 7632–7636.
10. Moustakas A, Heldin CH (2002) From mono- to oligo-Smads: the heart of the matter in TGF-beta signal transduction. Genes Dev 16: 1067–1071.
11. Chen Y, Bhushan A, Vale W (1997) Smad8 mediates the signaling of the ALK-2 [corrected] receptor serine kinase. Proc Natl Acad Sci U S A 94: 12938–12943.
12. Hoodless PA, Hargreaves T, Abdallah S, Stapleton M, O’Connor MB, et al. (1996) MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 85: 499–509.
13. Peng Y, Kang Q, Luo Q, Jiang W, Si W, et al. (2004) Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279: 32941–32949.
Activators of BMP Signaling

14. Ben-Arie N, Bellen HJ, Armstrong DL, McCull AE, Goerdadze PR, et al. (1997) 
Mahl1 is essential for genesis of cerebellar granule neurons. Nature 390: 169–172.

15. Jeong J, Kang DI, Lee GT, Kim IW (2010) Bone morphogenetic protein signaling: implications in urolith. Korean J Urol 51: 311–317.

16. Pinho RS, Andreoni S, Silva NS, Cappellano AM, Mastruca MR, et al. (2011) 
Pediatric central nervous system tumors: a single-center experience from 1989 to 2009. J Pediatr Hematol Oncol 33: 665–669.

17. Kieran MW, Walker DI, Frankaz D, Prados M (2010) Brain tumors: from childhood through adolescence into adulthood. J Clin Oncol 28: 4783–4789.

18. Ferretti E, De Smaele E, Po T, Dal員 T, Tosi E, et al. (2009) MicroRNA profiling in human medulloblastoma. Int J Cancer 124: 568–577.

19. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, et al. (2006) 
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24: 1924–1931.

20. Rios J, Alvarez-Rodrigue R, Marri E, Pons S (2004) 
Bmp2 antagonizes sonic hedgehog-mediated proliferation of cerebellar granule neurons through Smad5 signaling. Development 131: 3159–3168.

21. Zhao H, Ayrault O, Zindy F, Kim JH, Roussel MF (2008) Post-transcriptional regulation of Atoh1/Mahl1 by bone morphogenetic proteins suppresses medulloblastoma development. Genes Dev 22: 722–727.

22. Flora A, Klisch TJ, Schuster G, Zoghbi HY (2009) Deletion of Atoh1 disrupts Sonic Hedgehog signaling in the developing cerebellum and prevents medulloblastoma. Science 326: 1424–1427.

23. Kimura H, Ng JM, Curran T (2008) 
Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 13: 249–260.

24. Yauch RL, Djikgraaf GJ, Alebe I, Januario T, Ahn CP, et al. (2009) 
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326: 572–574.

25. Gottfried ON, Bailey AT (2008) Mesenchymal stem cell and gene therapies for spinal fusion. Neurosurgery 63: 380–391 discussion 391–392.

26. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, et al. (2004) 
Bmp2 antagonizes sonic hedgehog-mediated proliferation of cerebellar granule neurons through Smad5 signaling. Development 131: 3159–3168.

27. Uziel T, Zindy F, Kim JH, Roussef MF (2008) 
Post-transcriptional down-regulation of Atoh1/Mahl1 by bone morphogenetic proteins suppresses medulloblastoma development. Genes Dev 22: 722–727.

28. Flora A, Klisch TJ, Schuster G, Zoghbi HY (2009) Deletion of Atoh1 disrupts Sonic Hedgehog signaling in the developing cerebellum and prevents medulloblastoma. Science 326: 1424–1427.

29. Kimura H, Ng JM, Curran T (2008) 
Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 13: 249–260.

30. Zhao H, Ayrault O, Zindy F, Kim JH, Roussel MF (2008) Post-transcriptional regulation of Atoh1/Mahl1 by bone morphogenetic proteins suppresses medulloblastoma development. Genes Dev 22: 722–727.

31. Oetgen ME, Richards BS (2010) Complications associated with the use of bone morphogenetic protein in pediatric patients. J Pediatr Orthop 30: 192–198.

32. Korchynskyi O, ten Dijke P (2002) Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277: 4883–4891.

33. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, et al. (1998) Mesenchymal stem cells immortalization. Genes Dev 12: 2424–2433.

34. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Activity Relationship Study of Dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol 5: 245–253.

35. Makita H, Tanaka T, Fujitaka H, Tatsumata N, Satoh K, et al. (1996) 
Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin. Cancer Res 56: 4904–4909.

36. Androtzopoulos V, Wilsher N, Arso RR, Potter GA (2009) 
Bioactivation of the phytoestrogen isoflavin by CYPII1 cytochromes P450. Cancer Lett 274: 54–60.

37. Tsukamoto S, Abrutani M, Yoshiha T, Yamashita Y, El-Beih AA, et al. (2005) 
CYP3A4 inhibitors isolated from Licorice. Biol Pharm Bull 28: 2000–2002.

38. Nohe A, Hassel S, Ehrlich M, Neuhauer F, Schald W, et al. (2002) 
The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 277: 5330–5338.

39. Shin GC, Kim C, Lee JM, Cho WS, Lee SG, et al. (2009) 
Apgenin-induced apoptosis is mediated by reactive oxygen species and activation of ERK1/2 in rheumatoid fibroblast-like synoviocytes. Chem Biol Interact 182: 29–36.

40. Brunel B (1999) 
Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 26: 717–719.

41. Yang Y, Li X, Al-Lantik RS, Harris SE, Zhao J, et al. (2010) 
Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res 107: 252–262.

42. Yafe D, Sael O (1957) 
Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 206: 725–727.

43. Blau HM, Pavlath GK, Hardeman EC, Chiu CP, Silberstein L, et al. (1985) 
Plasticity of the differentiated state. Science 230: 758–766.

44. Li G, Peng H, Core K, Usas A, Olhanski A, et al. (2005) 
Differential effect of BMP4 on NIH/3T3 and C2C12 cells: implications for endochondral bone formation. J Bone Miner Res 20: 1611–1623.

45. Buring K, Semh H (1970) 
Enzyme patterns during bone induction. Calcif Tissue Res Suppl 102–104.

46. Vukicevic S, Laytenant F, Reddi AH (1989) 
Stimulation of the expression of osteogenic and chondrogenic phenotypes in vitro by osteogenin. Proc Natl Acad Sci U S A 86: 8793–8797.

47. Nishimura R, Kato Y, Chen D, Harris SE, Mundy GR, et al. (1998) 
Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem 273: 1872–1879.

48. Ham J, Ho JN, Lewis JA, Karin K, Daniels RN, et al. (2010) 
In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol 5: 245–253.

49. Lele Z, Bakkers J, Hammerschmidt M (2001) 
Morpholino phenocopies of the twist, smallheas, somitabun, silberblick, and pipetail mutations. Genesis 30: 190–194.

50. Fisher S, Amacher SL, Halpern ME (1997) Loss of cerebellum function centralizes the zebrafish embryo. Development 124: 1301–1311.

51. Little SC, Nullins MC (2004) 
Twisted gastrulation promotes BMP signaling in zebrafish dorsal-ventral axial patterning. Development 131: 5025–5035.

52. Cooper BJ, Key B, Carter A, Angil NZ, Hart DN, et al. (2006) 
Suppression and overexpression of adenovirofumycin hydrodise-like protein 1 (AHCVL1) influences zebrafish embryo development: a possible role for AHCYLV1 in inositol phospholipid signaling. J Biol Chem 281: 22471–22484.

53. Shen Q, Little SG, Xu M, Haupt J, Ast C, et al. (2009) 
The fibroblastosis of the zebrafish embryo. J Clin Invest 119: 3462–3472.